Our results may ultimately help to elucidate multiple key pathways to therapeutically target men who are carriers of a BRCA2 mutation with PCa to increase rates of cure by preventing rapid progression to mCRPC. This evidence concerns the gene BRCA2 and posterior cortical atrophy.